Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd banner

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874

Watchlist Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Logo
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874
Watchlist
Price: 16.78 HKD -0.83% Market Closed
Market Cap: HK$41.2B

EV/EBITDA

10.1
Current
6%
Cheaper
vs 3-y average of 10.7

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
10.1
=
Enterprise Value
HK$34.2B
/
EBITDA
¥3.3B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
10.1
=
Enterprise Value
HK$34.2B
/
EBITDA
¥3.3B

Valuation Scenarios

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (10.7), the stock would be worth HK$17.78 (6% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-1%
Maximum Upside
+187%
Average Upside
82%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 10.1 HK$16.78
0%
3-Year Average 10.7 HK$17.78
+6%
5-Year Average 10 HK$16.64
-1%
Industry Average 23.9 HK$39.9
+138%
Country Average 28.8 HK$48.11
+187%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
HK$34.2B
/
Jan 2026
¥3.3B
=
10.1
Current
HK$34.2B
/
Dec 2026
¥5.3B
=
6.5
Forward
HK$34.2B
/
Dec 2027
¥5.6B
=
6.1
Forward
HK$34.2B
/
Dec 2028
¥6.1B
=
5.6
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CN
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874
36.9B HKD 10.1 12.4
US
Eli Lilly and Co
NYSE:LLY
867B USD 28.4 42
US
Johnson & Johnson
NYSE:JNJ
555.4B USD 16.9 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.5 19.3
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 16.1 29.1
CH
Novartis AG
SIX:NOVN
221.8B CHF 12.4 20
US
Merck & Co Inc
NYSE:MRK
283.6B USD 9.7 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 7.9 10.7
US
Pfizer Inc
NYSE:PFE
151.6B USD 7.5 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
118.8B USD 7.1 16.9

Market Distribution

Lower than 78% of companies in China
Percentile
22st
Based on 5 409 companies
22st percentile
12.7
Low
0 — 16.3
Typical Range
16.3 — 53.1
High
53.1 —
Distribution Statistics
China
Min 0
30th Percentile 16.3
Median 28.8
70th Percentile 53.1
Max 49 021

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View

Market Cap
41.2B HKD
Industry
Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. stands as a prominent player in China's healthcare industry, weaving a rich legacy that dates back to its formation in the 20th century. Rooted in the dynamic city of Guangzhou, Baiyunshan reflects a harmonious blend of traditional Chinese medicine (TCM) and modern pharmaceutical innovation. The company's name itself, Baiyunshan—meaning "White Cloud Mountain" in Chinese—symbolizes its foundational connection to the city's cultural heritage and its aspiration to elevate healthcare standards. Baiyunshan's operations are a testament to its multifaceted approach to pharmaceutical production. It delves into the research and development, manufacturing, and distribution of both TCM and Western medicine. This dual approach enables Baiyunshan to cater to a diverse demographic, forging a unique path by merging ancient medical wisdom with cutting-edge scientific advancements. The core of Baiyunshan's business strategy pivots around its expansive product portfolio, which is instrumental in its revenue generation. Pharmaceuticals are at its heart, encompassing a wide range of products from patent medicines to essential drugs that are household names in China. Additionally, the company has successfully branched into the production of over-the-counter (OTC) products, health supplements, and even skincare products, broadening its consumer reach. Meanwhile, Baiyunshan's distribution network—extensive and strategically aligned—stretches across domestic and international markets, ensuring its products are widely accessible. By leveraging strategic partnerships and ongoing innovation, the company continually fortifies its market presence, making Baiyunshan a notable financial performer and a beacon of trust in the healthcare industry.

Intrinsic Value
25.42 HKD
Undervaluation 34%
Intrinsic Value
Price HK$16.78
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett